Of the 220,900 men estimated to be diagnosed with prostate cancer in 2004 in the U.S;about one half will undergo radical prostatectomy (RP) for treatment of their disease. As many as 25% or more men who undergo this treatment will experience a re-elevation in their serum Prostate Specific Antigen (PSA) level within months to years later. This rise in PSA after prostatectomy, termed biochemical recurrence or failure, is a clear indication of the proliferation of prostate cancer cells which escaped (metastasized) prior to prostatectomy. Statistically, more than one-third of men with biochemical recurrence develop clinically detectable metastatic disease (Pound 1999). This non-curable, lethal stage of prostate cancer claims over 29,000 lives in the U.S. annually. Clinicians are unable to predict with certainty which men are likely to fail therapy and subsequently develop metastatic disease and which are not. We hypothesize that the likelihood of disease recurrence after treatment of prostate cancer by RP is modified and/or determined by sequence variation in genes that regulate prostate cancer metastasis. Restating this hypothesis, genetic background is a determinant of metastatic potential.
The Specific Aims of this application are: 1) Explore the association between genetic variants in metastasis-related genes and disease progression in a case-control population of men who have undergone radical prostatectomy for treatment of clinically localized prostate cancer;cases are men whose disease progressed after surgical therapy, and controls are men whose disease did not progress;2) For genes demonstrating association with progression in Specific Aim 1, confirm the association in a second, similar case-control population;3) For genes associated in both populations, perform fine-mapping association tests, and assess association in non-European Americans cases;4) Assess genotype - phenotype correlation for progression associated genes. We anticipate that this study will provide novel insights into the mechanisms responsible for prostate cancer progression, and provide a basis for the identification of men at elevated risk for this life threatening event.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
3R01CA112517-05S1
Application #
7934195
Study Section
Special Emphasis Panel (ZRG1-HOP-N (02))
Program Officer
Elena, Joanne W
Project Start
2009-09-01
Project End
2010-08-31
Budget Start
2009-09-01
Budget End
2010-08-31
Support Year
5
Fiscal Year
2009
Total Cost
$99,950
Indirect Cost
Name
Johns Hopkins University
Department
Urology
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Liu, W; Lindberg, J; Sui, G et al. (2012) Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer. Oncogene 31:3939-48
Isaacs, William B (2012) Inherited susceptibility for aggressive prostate cancer. Asian J Androl 14:415-8
Dluzniewski, Paul J; Wang, Ming-Hsi; Zheng, Siqun Lilly et al. (2012) Variation in IL10 and other genes involved in the immune response and in oxidation and prostate cancer recurrence. Cancer Epidemiol Biomarkers Prev 21:1774-82
Schumacher, Fredrick R; Berndt, Sonja I; Siddiq, Afshan et al. (2011) Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet 20:3867-75
Ivansson, E L; Juko-Pecirep, I; Erlich, H A et al. (2011) Pathway-based analysis of genetic susceptibility to cervical cancer in situ: HLA-DPB1 affects risk in Swedish women. Genes Immun 12:605-14
Hsu, Fang-Chi; Sun, Jielin; Zhu, Yi et al. (2010) Comparison of two methods for estimating absolute risk of prostate cancer based on single nucleotide polymorphisms and family history. Cancer Epidemiol Biomarkers Prev 19:1083-8
Zheng, S Lilly; Stevens, Victoria L; Wiklund, Fredrik et al. (2009) Two independent prostate cancer risk-associated Loci at 11q13. Cancer Epidemiol Biomarkers Prev 18:1815-20
Liu, Wennuan; Sun, Jishan; Li, Ge et al. (2009) Association of a germ-line copy number variation at 2p24.3 and risk for aggressive prostate cancer. Cancer Res 69:2176-9
Lu, Lingyi; Sun, Jielin; Isaacs, Sarah D et al. (2009) Fine-mapping and family-based association analyses of prostate cancer risk variants at Xp11. Cancer Epidemiol Biomarkers Prev 18:2132-6
Hsu, Fang-Chi; Sun, Jielin; Wiklund, Fredrik et al. (2009) A novel prostate cancer susceptibility locus at 19q13. Cancer Res 69:2720-3

Showing the most recent 10 out of 24 publications